The metabolic tumour volume (MTV) is an independent prognostic indicator in diffuse large B-cell lymphoma (DLBCL). However, its measurement is not standardised and is subject to wide variations depending on the method used. This study aimed to compare the reproducibility of MTV measurement as well as the thresholds obtained for each method and their prognostic values. The baseline MTV was measured in 239 consecutive patients treated at Henri Becquerel Centre by two blinded evaluators. Eight methods were compared: 3 absolute (SUV (standardised uptake value) ≥ 2.5; SUV≥ liver SUVmax; SUV≥ PERCIST SUV), 1 percentage SUV threshold method (SUV ≥ 41% SUVmax) and 4 adaptive methods (Daisne, Nestle, Fitting, Black). The intraclass correlation coefficients were excellent, from 0.91 to 0.96, for the absolute SUV methods, Black and Nestle methods, and good for 41% SUVmax, Fitting and Daisne methods (0.82 to 0.88), with a significantly lower variability with absolute methods compared to 41% SUVmax ( < 0.04). Thresholds were found to be specific to each segmentation method and ranged from 295 to 552 cm. There was a strong correlation between the MTV and patient prognosis regardless of the segmentation method used ( = 0.001 for PFS and OS). The largest inter-observer cut-off variability was observed in the 41% SUVmax method, which resulted in more inter-observer disagreements in the classification of patients between high and low MTV groups. MTV measurements based on absolute SUV criteria were found to be significantly more reproducible than those based on 41% SUVmax criteria. The threshold was specific for each of eight segmentation methods, but all predicted prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911393PMC
http://dx.doi.org/10.3390/metabo11020072DOI Listing

Publication Analysis

Top Keywords

41% suvmax
20
absolute suv
12
diffuse large
8
large b-cell
8
b-cell lymphoma
8
methods compared
8
specific segmentation
8
segmentation method
8
methods
7
mtv
6

Similar Publications

Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using Ga-Pentixafor for Tumor Localization in Cushing Disease.

Radiology

December 2024

From the Department of Radiology (Yue Wu, S.W., W.R., Z. Yao), Department of Neurosurgery, Shanghai Pituitary Tumor Center (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.), Department of Nuclear Medicine and PET Center (Yanfei Wu, S.R., Y.G., F.X.), and Department of Endocrinology (M.H., S.Z., Y.Y., H.Y., Z.Z.), Huashan Hospital, Fudan University, 12 Wulumuqi Road, Shanghai 200040, China; Neurosurgical Institute of Fudan University, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); and Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Neuroendocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Mass (Q.Z.).

Background Gallium 68 (Ga) pentixafor has emerged as a potential C-X-C chemokine receptor type 4 (CXCR4)-targeted radiotracer for neuroendocrine tumor, yet its application in Cushing disease remains uncertain. Purpose To assess the diagnostic accuracy and value of Ga-pentixafor PET/MRI in localizing adrenocorticotropic hormone (ACTH)-secreting pituitary tumors in Cushing disease. Materials and Methods A prospective single-center study was conducted from March 2023 to February 2024 in participants with Cushing disease scheduled for surgical pituitary tumor resection.

View Article and Find Full Text PDF

Semiquantitative muscle parameters derived from FAPI and FDG PET/CT in evaluating sarcopenia among patients with malignant tumors.

Nucl Med Commun

December 2024

PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University.

Background: The objective of this study is to explore and compare the potential utility of fibroblast activation protein inhibitor (FAPI) and fluorodeoxyglucose PET/computed tomography (CT) in assessing sarcopenia among patients with malignant tumors.

Methods: A retrospective analysis was conducted on 127 patients with histologically confirmed malignant tumors who underwent both 18F/68Ga-FAPI and fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT scans. Clinical characteristics and PET/CT parameters of maximum and mean standard uptake value (SUVmax and SUVmean) of muscle at the 3rd lumbar (L3) level were reviewed.

View Article and Find Full Text PDF

Objective: To analyze the application value of standardized uptake value (SUV) in quantitative single-photon emission computed tomography/computed tomography (SPECT/CT) based on the maximum expectation reconstruction algorithm for diagnosing benign and malignant bone lesions.

Subjects And Methods: A retrospective analysis was conducted on the clinical data of 83 patients suspected of bone metastasis who underwent quantitative SPECT/CT bone scans in our hospital from September 2023 to July 2024. A total of 91 high-metabolic bone lesions were outlined for SUV measurement, while the spinal SUV of patients with normal bone metabolism were outlined as the control group (46 vertebral bodies).

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to evaluate disease-free survival (DFS) and progression-free survival (PFS) in nasopharyngeal cancer patients after chemoradiation, focusing on those with complete and partial metabolic responses as measured by PET/CT scans.
  • - Results indicated that patients with a complete metabolic response had significantly better DFS (60.157 months) compared to the PFS of those with partial response (8.145 months), with certain factors like SUVmax and tumor size being linked to poorer outcomes.
  • - Key findings showed 84% of responders experienced DFS with a low recurrence rate, while non-responders had more disease progression, and no significant predictors for PFS were identified among non-responders.
View Article and Find Full Text PDF

Evaluating the diagnostic performance of [F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [F]FDG PET/CT.

Eur Radiol

November 2024

Department of PET-CT Center, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Purpose: To compare the diagnostic value of [F]ALF-NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) and F-fluorodeoxyglucose (FDG) PET/CT in gastric cancer.

Methods: This single-center retrospective analysis included 65 patients with gastric cancer who received both [F]FDG and [F]ALF-NOTA-FAPI-04 PET/CT for initial staging or restaging. Histopathological manifestations, typical imaging manifestations, follow-up imaging, and comprehensive clinical assessment were used as reference criteria.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!